Physician profile
Bency John Sony
NPI 1932665304
$1,561.42
in general payments reported to CMS, 2019-2025
21 companies · $1,079 in 2025
The $1,079 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $46.21 · 2024: $437 · 2025: $1,079.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,561.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,561.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $460.93 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $172.99 | 2024-2025 | |
| Exact Sciences Corporation | $106.00 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $102.98 | 2024-2025 | Ozempic, Wegovy |
| Otsuka America Pharmaceutical, INC. | $95.67 | 2025 | Rexulti |
| Lilly USA, LLC | $62.21 | 2024-2025 | Mounjaro, Zepbound |
| Dexcom, INC. | $61.31 | 2023-2024 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $53.12 | 2024-2025 | Trintellix |
| Sanofi Pasteur INC. | $53.01 | 2024-2025 | |
| Abbvie INC. | $51.08 | 2025 | |
| Gilead Sciences, INC. | $49.37 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $47.41 | 2024-2025 | Caplyta |
| Amgen INC. | $46.30 | 2025 | Prolia, Evenity |
| Glaxosmithkline, LLC. | $40.87 | 2024-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Phathom Pharmaceuticals, INC. | $31.56 | 2025 | Voquezna |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $28.17 | 2024-2025 | Zoryve |
| Lundbeck LLC | $25.17 | 2024 | Rexulti |
| Medtronic, INC. | $23.05 | 2025 | Intellis Adaptivestim |
| Abbott Laboratories | $18.64 | 2024 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $16.86 | 2025 | |
| Sanofi-Aventis U.S. LLC | $14.72 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bency Sony listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.